Insulet Corp is a healthcare company specializing in the development and manufacturing of innovative insulin delivery systems for individuals with diabetes. The company is best known for its Omnipod Insulin Management System, a tubeless, waterproof device that allows users to deliver insulin discreetly and conveniently without the need for traditional syringes or infusion sets. Insulet is committed to enhancing the quality of life for diabetes patients by providing advanced technology solutions that simplify insulin management, improve glycemic control, and promote independence in self-care. Through ongoing research and development, Insulet aims to lead the way in diabetes management innovation. Read More
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the commercial launch of its Omnipod 5 Automated Insulin Delivery System and its proprietary data management system Omnipod Discover™ in Spain, the Company’s newest European market. Spain is the 26th country where Insulet sells Omnipod, and the 20th country where Omnipod 5 is available, further accelerating Insulet’s mission to transform the lives of people with diabetes around the world.
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026, inclusive (the “Class Period”). Insulet develops, manufactures, and sells insulin delivery systems.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Insulet Corporation (“Insulet” or “the Company”) (NASDAQ: PODD) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Insulet Corporation (“Insulet” or the “Company”) (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026, inclusive (the “Class Period”). Insulet investors have until August 31, 2026 to file a lead plaintiff motion.
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Insulet Corporation (NASDAQ: PODD) securities between February 21, 2025 and May 26, 2026. Insulet develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the U.S. and internationally.
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the second quarter of 2026 on Wednesday, August 5, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time).
As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the patient monitoring industry, including...
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Jonathan (“Jay”) Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mr. Mazelsky joins the Board as an independent director.
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced new clinical results highlighting the next breakthroughs in tubeless Automated Insulin Delivery (AID) systems. The data and growing body of evidence not only confirm the impact of Insulet’s technology today—it also fuels continued investment in breakthrough innovation designed to improve outcomes, reduce daily effort, and expand access to diabetes technology.
DexCom posts steady profits and global reach, while Insulet surges ahead with rapid revenue growth and a focused product line. Which strategy stands out?
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 in New Orleans.
Shareholders of Insulet would probably like to forget the past six months even happened. The stock dropped 54.4% and now trades at $144.10. This might have i...
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. rollout of new algorithm enhancements for the Omnipod 5 Automated Insulin Delivery (AID) System. The updates follow FDA 510(k) clearance in December 2025. Omnipod 5 is also now compatible in the U.S. with Abbott’s Libre 3 Plus sensor, expanding choice for people with diabetes.
